Fevaxyn Pentofel


inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 10/04/2017

Authorisation details

Product details
Fevaxyn Pentofel
Agency product number
Active substance
  • inactivated feline calicivirus / inactivated feline Chlamydophila felis / inactivated feline leukaemia virus / inactivated feline panleukopenia virus
  • inactivated feline rhinotracheitis virus
International non-proprietary name (INN) or common name
inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA 
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Zoetis Belgium SA
Rue Laid Burnait, 1
1348 Louvain-la-Neuve

Product information

23/03/2017 Fevaxyn Pentofel - EMEA/V/C/000030 - IG/0747


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

For the active immunisation of healthy cats nine weeks or older against feline panleukopenia and feline leukaemia viruses and against respiratory diseases caused by feline rhinotracheitis virus, feline calicivirus and Chlamydophila felis.

Assessment history

How useful was this page?

Add your rating